No Data
No Data
Guangshengtang (300436.SZ) reported 2023 annual results, with a net loss of 349 million yuan, an increase in year-on-year losses
Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...
Express News | Guangshengtang: The innovative hepatitis B core protein inhibitor GST-HG141 has obtained a US Patent Authorization Notice and an Australian Patent Certificate; in addition, the novel c-Met targeted drug GST-HG161 has also obtained a Peruvian Patent Author
Guangshengtang (300436.SZ): Obtaining a patent certificate or authorization notice for a new drug under development
Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development. The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel, and have been exhausted up to now
Express News | Guangshengtang: Plans to terminate some technical service contracts
Express News | Guangshengtang: Phase II III clinical research data for a class of innovative anti-COVID-19 drugs will be published in the authoritative international journal “eClinical Medicine”
Guangshengtang (300436.SZ) subsidiaries obtained patent certificates or authorization notices for various innovative drugs
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary...
No Data